English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Rationale: Carriers of the most common prothrombotic mutations FVL (factor V Leiden) and FII (prothrombin) 20210G&gt;A show a highly variable clinical phenotype. Using standardized in vivo coagulation activation followed by activity pattern analysis we have recently shown, that the FVL mutation accelerates thrombin and APC (activated protein C) formation in carriers without a history of venous thromboembolism (VTE). Objective: The aim of this prospective cohort study was to investigate, if the FII 20210G&gt;A mutation induces a similar reaction pattern, and if the response rates differ in FVL and FII 20210G&gt;A mutation carriers with prior VTE (VTE+). Methods and Results: We comparatively analyzed 30 FVL carriers, 28 FII 20210G&gt;A carriers (thereof 13 VTE+ each) and 15 healthy controls. Changes in plasma levels of thrombin, prothrombin activation fragment 1+2 (F1+2), TAT (thrombin-antithrombin complex), APC, and D-dimer were monitored over 8 hours after infusion of recombinant factor VIIa (15 µg/kg). An increase of F1+2 and TAT levels was observed, that did neither differ between FVL and FII 20210G&gt;A carriers nor between asymptomatic and VTE+ carriers of these mutations. Median plasma levels of APC increased more (P =0.008) in FVL carriers (from 1.39 to 7.79 pmol/L) than in FII 20210G&gt;A carriers (from 1.03 to 5.79 pmol/L), and more in FII 20210G&gt;A carriers (P =2×10–4 ) than in healthy controls (from 0.86 to 3.00 pmol/L). Most importantly, however, the APC response was greater (P =0.015) in asymptomatic (n=13) than in VTE+ (n=12) heterozygous FVL carriers, with an increase of APC levels from 1.44 to 8.11 pmol/L versus 1.27 to 5.62 pmol/L.Conclusions: These in vivo data demonstrate that the FII 20210G&gt;A and FVL mutations share an intermediate phenotype that is characterized by increased thrombin formation after coagulation activation. Furthermore, our data support the conclusion that the APC activating capacity of FVL carriers modifies the thrombotic risk of this common prothrombotic mutation.

Increased Activated Protein C Response Rates Reduce the Thrombotic Risk of Factor V Leiden Carriers But Not of Prothrombin 20210G>A Carriers